Loading quotes...

Forecast

The analysts' average price target is €10.28 (-18.41%). The median is €10.89 (-13.57%).

Buy	2
Hold	4
Sell	3

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Organon Company: five-year investment would have lost about 61.4%

An investment of $10,000 in Organon Company shares on 22 October 2021 would have been worth only $3,855.86 at the close on 21 October 2026, representing a loss of 61.44%. The closing price on 21 October 2026 was $13.75 and the market capitalization was about $3.60 billion. The calculation does not take stock splits or dividend payments into account. » More on finanzen.net
Organon Company: stock rises 34.7% over one year

A year ago the Organon Company share closed at $10.24; it most recently traded at $13.79, corresponding to a performance of +34.67%. An investment of $100 a year ago would therefore be worth about $134.67 today. Market capitalization is most recently around $3.61 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net
Organon Company stock falls 59.25% over five years

Five years ago the Organon Company stock closed at $33.69; on 23.09.2026 the price was $13.73. An investment of $1,000 five years ago would be worth about $407.54 today, a decline of 59.25%. Market capitalization is most recently given as $3.59 billion. The calculation does not take stock splits and dividends into account. » More on finanzen.net
Organon Company: investment three years ago would be down about 30.04%

Someone who had invested 100 USD in Organon Company three years ago would now own 5.118 shares and the value would be 69.96 USD, representing a loss of 30.04%. The stock's closing price is reported at 13.67 USD, while the price back then was 19.54 USD. Market value most recently at 3.59 billion USD; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net
Organon: FDA reviews extension of approval for copper IUD MIUDELLA to six years

The FDA has accepted an application seeking to extend the approved duration of use for the hormone-free copper IUD MIUDELLA from three to six years; a decision is expected in the second quarter of 2027. Organon expects commercial availability by the end of 2026 and had licensed worldwide rights to MIUDELLA from Sebela Women’s Health. Phase‑3 data in 1,904 women showed a Pearl index of 0.94 in the first year and 1.05 over three years (effectiveness ~99%); common adverse events were heavier menstrual bleeding, pain and intermenstrual bleeding. The product includes a Risk Evaluation and Mitigation Strategy and requires certification and registration of medical personnel before dispensing and insertion. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Organon has already paid €0.0519 in dividends. The last payout was in September.

Financials

In the last quarter, Organon had revenue of €1.39bn and net profit of €144.79m

(EUR)	September 2026	YoY
Revenue	1.39bn	1.79%
Gross profit	767.2m	5.06%
Net profit	144.79m	6.20%
EBITDA	391.1m	0.87%

Fundamentals

Metric	Value
Market capitalization	€3.31bn
Number of shares	262.62m
52-week high/low	€12.61 - €5.16
Dividend yield	0.55%
Dividends TTM	€0.0689
Next dividend	€0.0181
Beta	1.52
P/E ratio	17.59
PEG ratio	-0.30
P/B ratio	3.06
P/S ratio	0.60

Company profile

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Name	Organon
CEO	Joseph T. Morrissey Jr.
Headquarters	Jersey City, nj USA
Website	organon.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	29/11/2018
Employees	10,000